Compass Pathways Plc (CMPS)
Compass Pathways Plc (CMPS) experienced a decline of 0.5 % during the 24‑hour period ending at 11:16 AM Central Europe on Thursday, 22 October 2026. The shares traded at approximately USD 11.84 on major exchanges.
- Outstanding shares: 138.5 million
- Market capitalisation: USD 1.6 billion
- Volume (last 24 h): USD 21.6 million worth of shares traded
- Year‑to‑date performance: 19.89 % decline since the previous month‑end
- Simple moving average (200 days): USD 10.25
- 52‑week high: USD 15.87 (9 September 2026)
- 52‑week low: USD 4.88 (24 March 2026)
Recent performance of peer companies
| Stock | 24‑hour movement | Current price | Market capitalisation | P/E ratio |
|---|---|---|---|---|
| Immunocore (IMCR) | –1.56 % | USD 32.09 | USD 1.7 billion | – |
| Unilever (ULVR.L) | –1.70 % | GBX 4,848 | GBX 143 billion | 23.38 |
| Rolls‑Royce (RR.L) | +0.36 % | GBX 1,293.2 | GBX 146.9 billion | 36.64 |
| Nomad Foods (NOMD) | –1.58 % | USD 11.80 | USD 1.7 billion | 12.32 |
| Global Ship Lease (GSL) | +1.48 % | USD 41.83 | USD 1.5 billion | 3.98 |
Unilever and Rolls‑Royce showed modest gains during the week, while Immunocore, Nomad Foods, and Global Ship Lease remained below their previous closing prices.
Company overview
Compass Pathways Plc is headquartered in Altrincham, United Kingdom. The company focuses on developing psilocybin‑based therapies for treatment‑resistant depression. Its services are delivered to patients and healthcare providers across Europe and North America. Compass Pathways is listed on the Nasdaq stock exchange and maintains an online presence at www.compasspathways.com .
